Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
Atlanta News First on MSN57m
Cobb County files lawsuit against insulin manufacturers, pharmacy benefit managers for alleged price fixingCobb County has filed a lawsuit accusing several major insulin manufacturers and pharmacy benefit managers (PBMs) of ...
Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...
CVS Caremark, OptumRx and St. Louis-based Express Scripts — are part of huge health conglomerates that also own insurers, ...
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
In the debate over the high cost of prescription drugs, pharmacy benefit managers are hotly contested. PBMs, the middlemen in ...
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
The Federal Trade Commission found Pharmacy Benefit Managers profited billions by raising the prices of "specialty drugs." ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback